Exabis Library
Welcome to the e-CCO Library!
P500: Capsule endoscopy reveals small intestinal mucosal Crohn’s disease healing after treatment with adalimumab: preliminary results of the SIMCHA study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P500: Effectiveness and safety in Crohn's disease patients who were treated with CT-P13
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P500: Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P500: Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P500: The effects of EBV naïve status on treatment decisions in patients with inflammatory bowel disease: Does the risk of GI lymphoma justify the cost?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P500: The use of budesonide results in lower risk for infections compared to systemic glucocorticoids
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P501 Thiopurine withdrawal in patients with Crohn’s disease: the SURESTE study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P501: Abdominal obesity in Paediatric Crohn’s disease is associated with adipokine dysregulation
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P501: Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P501: High TNF-production of CD14+ cells and short disease duration are independent predictive factors for response to Infliximab treatment
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P501: Incidence and therapeutic management/treatment of very early onset inflammatory bowel disease during 2015-2020.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P501: Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P501: Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reports
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P501: Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P502 Tumour necrosis factor antagonists are superior to anti-integrin and anti-IL-12/23 therapies for preventing postoperative recurrence in adult Crohn’s disease patients requiring postoperative therapy
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P502: Application of an algorithm-based precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: implications for drug usage and cost
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P502: Clinical and endoscopic features of secondary loss of response cases in patients with Crohn’s disease treated with infliximab by top-down strategy: A case–control study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P502: Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P502: Dietary habits and nutritional status in children and adolescents with Inflammatory Bowel Disease: an italian multicenter case-control study (NUTRIBD study)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P502: Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from China
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM